Cost-of-care discussions rarely documented for patients with advanced cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A large population-based pilot study led by researchers at the American Cancer Society and NCI shows cost discussions were infrequently documented in medical records of patients diagnosed with advanced non-small cell lung cancer and melanoma, which may hinder identifying patient financial needs and tracking outcomes of associated referrals. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login